Related Experiment Video

Updated: Aug 24, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent

R J Firpi1, T T Tran, P Flores

  • 1Center for Liver Diseases and Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Alimentary Pharmacology & Therapeutics
|April 29, 2004
PubMed
Abstract

Insights

Sirolimus can cause serious hypertriglyceridaemia in transplant patients. Discontinuing sirolimus effectively resolved or improved lipid levels in all reported cases.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Sirolimus is an immunosuppressant used in transplantation, valued for low nephrotoxicity.
  • Concerns exist regarding sirolimus's safety and side effects, particularly dyslipidemia, in liver transplantation.
  • Hypertriglyceridemia is a frequent, often refractory, adverse event associated with sirolimus therapy.

Purpose of the Study:

  • To investigate the impact of sirolimus on lipid levels in transplant recipients.
  • To assess the safety and efficacy of sirolimus in liver transplantation.
  • To evaluate management strategies for sirolimus-induced hypertriglyceridemia.

Main Methods:

  • Case series of six patients experiencing significant hyperlipidemia during sirolimus treatment.
  • Monitoring of lipid profiles in patients receiving therapeutic trough levels of sirolimus.

Main Results:

  • All six patients developed significant hyperlipidemia despite therapeutic sirolimus trough levels.
  • Hypertriglyceridemia was a prominent adverse effect observed in the patient cohort.

Conclusions:

  • Discontinuation of sirolimus led to resolution or improvement of hyperlipidemia in all patients.
  • Sirolimus cessation is an effective strategy for managing sirolimus-induced hypertriglyceridemia.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...